Beamtree Appoints Stepniak as CEO with $450K Salary and 4 Million Performance Rights

Leadership Transition at Beamtree

Beamtree Holdings Limited (ASX: BMT), a prominent player in AI-driven healthcare decision support and data insights, has announced a pivotal leadership change with the appointment of Marek Stepniak as its new Chief Executive Officer, effective early March 2025. Stepniak, who has served as Beamtree’s Chief Growth Officer for the past 18 months, steps into the role following the retirement of founding CEO Tim Kelsey.

This transition marks a strategic continuity for Beamtree as it seeks to consolidate and expand its footprint in the global healthcare technology market. Stepniak’s promotion from within signals confidence in his leadership and vision, particularly given his instrumental role in spearheading the company’s recent international expansion efforts.

Global Expansion and Market Penetration

Stepniak brings a wealth of experience from over 30 countries, including key regions such as the Middle East, Europe, Asia, and North America. His background includes leadership roles in hospital groups and health technology organizations, as well as a tenure as a healthcare partner at McKinsey & Company. Under his stewardship as Chief Growth Officer, Beamtree secured significant contracts, including National PICQ licenses with Saudi Arabia’s Centre for National Health Insurance, coding services with the Middle East’s largest private hospital group, and AI autonomous coding implementations with NHS Trusts in England.

These wins underscore Beamtree’s growing influence across diverse healthcare systems and its ability to tailor AI and data solutions to varying regulatory and operational environments. The company’s product suite spans diagnostic technology, clinical decision support, coding assistance, and analytics networks, positioning it well to capitalize on the increasing demand for data-driven healthcare innovation.

Strategic Continuity and Governance

While Tim Kelsey steps down as CEO, he will remain closely involved as a part-time senior advisor and will chair Beamtree’s Global Impact Committee (GIC). The GIC plays a crucial role in shaping the company’s strategic direction on health data innovation and best practices, reinforcing Beamtree’s mission to harness data for improved patient outcomes worldwide.

Emma Gray, Chair of Beamtree, emphasized the thorough global search process that culminated in Stepniak’s appointment, highlighting his entrepreneurial drive and proven track record in enterprise sales across key international markets. This leadership continuity is designed to sustain momentum and accelerate growth as Beamtree prepares to release further details on new contracts and pipeline developments in its upcoming half-year results.

Compensation and Incentives

Stepniak’s remuneration package includes a fixed annual salary of $450,000, supplemented by a sign-on grant of 350,000 fully paid ordinary shares and performance rights tied to fiscal year 2025 and 2026 milestones. These incentives align his interests closely with shareholder value creation and the company’s long-term strategic objectives.

As Beamtree navigates a competitive and rapidly evolving healthcare technology landscape, Stepniak’s leadership will be critical in leveraging AI and data analytics to deliver scalable solutions that improve healthcare delivery globally.